Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRE-08: Oral CMC for Early-Stage Breast Cancer
NCT06085742Phase 2Recruiting
- Sponsor
- University of Illinois Chicago
- Start
- Nov 2023
- Primary completion
- Sep 2034
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, methotrexate and capecitabine in breast cancer, sponsored by University of Illinois Chicago. Primary endpoint: Relative Dose Intensity at 1 year. Started Nov 2023; status: recruiting.
02
Drugs
cyclophosphamidemethotrexatecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06085742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06085742.